Fig 3
From: Glutaminase-1 (GLS1) inhibition limits metastatic progression in osteosarcoma
Metabolic analysis of MG63.3 cells treated with CB-839 and metformin alone and in combination in vivo. a–c Cellular oxygen consumption rates (OCR) of CB-839, metformin, and combination-treated MG63.3 cells were measured using a Seahorse Bioscience XFe96 Extracellular Flux Analyzer. d Glutamate-related metabolites quantified upon CB8-39, metformin and combo treatment in MG63.3 cells (in quadruplex) by 1H NMR spectroscopy. Data displayed as mean ± SD, *p < 0.05, **p < 0.01, ***p < 0.001 (ANOVA followed by multiple comparisons “vehicle vs each treatment”)